Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 101 OP01-04 | DOI: 10.1530/endoabs.101.OP-01-04

ETA2024 Oral Presentations Oral Session 1: Topic Highlights (6 abstracts)

Unveiling severe adverse events of antithyroid drugs in patients with graves’ disease; a real-world multicenter cohort study

Soo Myoung Shin 1 , Yeji Lee 2 , Jimi Choi 3 , Yoo Hyung Kim 4 , Kyoung Jin Kim 5 , Kyeong Jin Kim 6 , Young Joo Park 7 & Sin Gon Kim 3


1Korea University Anam Hospital, Department of Internal Medicine, Seoul, Korea, Rep. of South; 2Korea University Anam Hospital, Internal Medicine, Seoul; 3Korea University Colleg of Medicine, Internal Medicine, Seoul, Korea, Rep. of South; 4Seoul National University Hospital, Endocrinology and Metabolism, Seoul, Korea, Rep. of South; 5Korea University Anam Hospital, Internal Medicine, Seoul, Korea, Rep. of South; 6Korea University College of Medicine, Internal Medicine, Seoul, Korea, Rep. of South; 7Seoul National University Hospital, Seoul, Korea, Rep. of South


Objectives: Although antithyroid drugs (ATD) offer potent therapeutic benefits for treating Graves’ disease (GD), they can occasionally lead to rare, potentially life-threatening adverse events (AEs), such as agranulocytosis or toxic hepatitis. As the incidence and characteristics of these life-threatening AEs in Korea have not been widely investigated, we aimed to identify the real-world features of ATD-related severe AEs.

Method: We analyzed 19,975 patients (14,444 women; mean age, 42.9 ± 14.2 years) diagnosed with GD at four tertiary referral hospitals between 2002 and 2020, with a median follow-up time of 19.9 months. GD was defined as cases with the ICD-10 code E05 and those who have received ATD at least once. Agranulocytosis was defined as absolute neutrophil count (ANC) <500/µL; toxic hepatitis was defined as aminotransferase >5 times the upper limit of normal (ULN), total bilirubin >3 times the ULN, or prothrombin time-international normalized ratio >1.5 times the ULN.

Results: Agranulocytosis occurred in 50 (0.25%) patients; moderate neutropenia (500≤ANC<1000/µl), in 222 (1.11%); and mild neutropenia (1000≤ANC <1500/µl), in 947 (4.74%). The incidence of ATD-induced toxic hepatitis was 1.80% (359/19,975). The median time to onset of agranulocytosis was 39.5 days (Interquartile range [IQR], 27-303 days), while for toxic hepatitis, it was 64 days (IQR 21-355 days). Among patients with agranulocytosis, methimazole (MMI) was used in 38 (76%) and propylthiouracil (PTU) in 13 (26%). Regarding toxic hepatitis, 270 patients (75.2%) received MMI and 33 (9.19%) received PTU. Six individuals (0.03%) required liver transplantation, and there were no cases of bone marrow transplantation. The daily mean dosage of ATD increased the risk of agranulocytosis (adjusted OR 1.01, 95% CI 1.01-1.02), and toxic hepatitis (crude OR 1.01, 95% CI 1.007-1.014). Other risk factors for toxic hepatitis included male gender, older age, PTU use, and underlying liver disease.

Conclusions: The incidence of ATD-induced agranulocytosis and toxic hepatitis is comparable to previously reported rates. However, actual life-threatening AEs seem to be rare in Korea.

Volume 101

46th Annual Meeting of the European Thyroid Association (ETA) 2024

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.